Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

David Olmos; Daniel Brewer; Jeremy Clark; Daniel C Danila; Chris Parker; Gerhardt Attard; Martin Fleisher; Alison Hm Reid; Elena Castro; Shahneen K Sandhu; Lorraine Barwell; Nikhil Babu Oommen; Suzanne Carreira; Charles G Drake; Robert Jones; Colin S Cooper; Howard I Scher; Johann S de Bono

doi:10.1016/S1470-2045(12)70372-8

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

David Olmos, Daniel Brewer, Jeremy Clark, Daniel C Danila, Chris Parker, Gerhardt Attard, Martin Fleisher, Alison Hm Reid, Elena Castro, Shahneen K Sandhu, Lorraine Barwell, Nikhil Babu Oommen, Suzanne Carreira, Charles G Drake, Robert Jones, Colin S Cooper, Howard I Scher, Johann S de Bono

Research output: Contribution to journal › Article › peer-review

96 Citations (Scopus)

Abstract

Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome.

Original language	English
Pages (from-to)	1114-24
Number of pages	11
Journal	The Lancet Oncology
Volume	13
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(12)70372-8
Publication status	Published - Nov 2012

Keywords

Aged
Aged 80 and over
Castration
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Inflammation
Male
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Prospective Studies
Prostatic Neoplasms
Messenger RNA
Survival Analysis
Tumor Markers (Biological)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(12)70372-8

Cite this

Olmos, D., Brewer, D., Clark, J., Danila, D. C., Parker, C., Attard, G., Fleisher, M., Reid, A. H., Castro, E., Sandhu, S. K., Barwell, L., Oommen, N. B., Carreira, S., Drake, C. G., Jones, R., Cooper, C. S., Scher, H. I., & de Bono, J. S. (2012). Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. The Lancet Oncology, 13(11), 1114-24. https://doi.org/10.1016/S1470-2045(12)70372-8

Olmos, David ; Brewer, Daniel ; Clark, Jeremy ; Danila, Daniel C ; Parker, Chris ; Attard, Gerhardt ; Fleisher, Martin ; Reid, Alison Hm ; Castro, Elena ; Sandhu, Shahneen K ; Barwell, Lorraine ; Oommen, Nikhil Babu ; Carreira, Suzanne ; Drake, Charles G ; Jones, Robert ; Cooper, Colin S ; Scher, Howard I ; de Bono, Johann S. / Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer : a prospective, two-stage study. In: The Lancet Oncology. 2012 ; Vol. 13, No. 11. pp. 1114-24.

@article{c85c91da8fec44889ef6c75247a23012,

title = "Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study",

abstract = "Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome.",

keywords = "Aged, Aged 80 and over, Castration, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Inflammation, Male, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Prospective Studies, Prostatic Neoplasms, Messenger RNA, Survival Analysis, Tumor Markers (Biological)",

author = "David Olmos and Daniel Brewer and Jeremy Clark and Danila, {Daniel C} and Chris Parker and Gerhardt Attard and Martin Fleisher and Reid, {Alison Hm} and Elena Castro and Sandhu, {Shahneen K} and Lorraine Barwell and Oommen, {Nikhil Babu} and Suzanne Carreira and Drake, {Charles G} and Robert Jones and Cooper, {Colin S} and Scher, {Howard I} and {de Bono}, {Johann S}",

year = "2012",

month = nov,

doi = "10.1016/S1470-2045(12)70372-8",

language = "English",

volume = "13",

pages = "1114--24",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier",

number = "11",

}

Olmos, D, Brewer, D , Clark, J, Danila, DC, Parker, C, Attard, G, Fleisher, M, Reid, AH, Castro, E, Sandhu, SK, Barwell, L, Oommen, NB, Carreira, S, Drake, CG, Jones, R, Cooper, CS, Scher, HI & de Bono, JS 2012, 'Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study', The Lancet Oncology, vol. 13, no. 11, pp. 1114-24. https://doi.org/10.1016/S1470-2045(12)70372-8

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer : a prospective, two-stage study. / Olmos, David; Brewer, Daniel ; Clark, Jeremy; Danila, Daniel C; Parker, Chris; Attard, Gerhardt; Fleisher, Martin; Reid, Alison Hm; Castro, Elena; Sandhu, Shahneen K; Barwell, Lorraine; Oommen, Nikhil Babu; Carreira, Suzanne; Drake, Charles G; Jones, Robert; Cooper, Colin S; Scher, Howard I; de Bono, Johann S.

In: The Lancet Oncology, Vol. 13, No. 11, 11.2012, p. 1114-24.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer

T2 - a prospective, two-stage study

AU - Olmos, David

AU - Brewer, Daniel

AU - Clark, Jeremy

AU - Danila, Daniel C

AU - Parker, Chris

AU - Attard, Gerhardt

AU - Fleisher, Martin

AU - Reid, Alison Hm

AU - Castro, Elena

AU - Sandhu, Shahneen K

AU - Barwell, Lorraine

AU - Oommen, Nikhil Babu

AU - Carreira, Suzanne

AU - Drake, Charles G

AU - Jones, Robert

AU - Cooper, Colin S

AU - Scher, Howard I

AU - de Bono, Johann S

PY - 2012/11

Y1 - 2012/11

N2 - Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome.

AB - Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome.

KW - Aged

KW - Aged 80 and over

KW - Castration

KW - Gene Expression Profiling

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Inflammation

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Metastasis

KW - Neoplasm Staging

KW - Prognosis

KW - Prospective Studies

KW - Prostatic Neoplasms

KW - Messenger RNA

KW - Survival Analysis

KW - Tumor Markers (Biological)

U2 - 10.1016/S1470-2045(12)70372-8

DO - 10.1016/S1470-2045(12)70372-8

M3 - Article

C2 - 23059046

VL - 13

SP - 1114

EP - 1124

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 11

ER -